WHO Panel To Decide On Covaxin Emergency Use On Wednesday
NDTV
Bharat Biotech's Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant.
The Technical Advisory Group (TAG), an independent advisory panel of the World Health Organisation (WHO), has sought additional clarifications from Bharat Biotech, the manufacturer of Covaxin, in order to conduct a final Emergency Use Listing (EUL) risk-benefit assessment for global use of the vaccine.
Replying to an ANI query, a WHO official, "The TAG met on October 26, 2021, and decided to seek additional clarifications from the Covaxin manufacturers that are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine."
"The TAG expects to receive these clarifications from the manufacturer by the end of this week and aims to reconvene for the final risk-benefit assessment on Wednesday, 3 November," read the statement from WHO.
The Technical Advisory Group for Emergency Use Listing (TAG-EUL) is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.
